| Zugriffe | |
|---|---|
| CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab | 295 |
| Juni 2025 | Juli 2025 | August 2025 | September 2025 | Oktober 2025 | November 2025 | Dezember 2025 | |
|---|---|---|---|---|---|---|---|
| CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab | 1 | 1 | 1 | 24 | 25 | 7 | 2 |
| Zugriffe | |
|---|---|
| s12967-015-0456-6.pdf | 205 |
